Table 7 Included studies—nonsurgical treatment of peri-implantitis: adjunctive antiseptic therapy

Machtei et al. [23]

Multicentre RCT, parallel

60 patients

PD = 6–10 mm and BOP + radiographic bone loss

6 months

OHI + ultrasonic debridement + matrix containing 2.5-mg CHX chips (i.e. up to 4 per implant site)

OHI + ultrasonic debridement + biodegradable crosslinked gelatin matrix chip

Test

77 implants

Repeated application at sites with PD ≥6 mm at 2, 4, 6, 8, 12 and 18 weeks

Repeated application at sites with PD ≥6 mm at 2, 4, 6, 8, 12 and 18 weeks

BOP: 100 (0.0) (BL) to 42.5 (50.0) % (6 months, subject level)

PD: 7.6 (1.1) (0.0) to 5.47 (1.86) mm (6 months, subject level)

Control

BOP: 100 (0.0) (BL) to 54.5 (50.5) % (6 months, subject level)

PD: 7.21 (1.08) (BL) to 5.48 (1.25) mm (6 months, subject level)

BOP and PD reductions at 6 months not sign. different between groups